Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study.

By P. Jourdain, G. Jondeau, F. Funck, P. Gueffet, A. le Helloco, E. Donal, J. Aupetit, M. Aumont, M. Galinier, J. Eicher and 2 more. Journal of the American College of Cardiology, 2007

702 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Surgery

View Paper: https://www.semanticscholar.org/paper/16ce44906412019121822897e3fe53034f10ab83

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. M. Gheorghiade
2. G. Fonarow
3. J. Cleland
4. Gerasimos Filippatos
5. E. Braunwald
6. S. Anker
7. C. Yancy
8. M. Drazner

In Endocrinology, Diabetes and Metabolism

1. A. Rhodes
2. Véronique L. Roger

In Surgery

1. E. Braunwald

Citations in the corpus

• State of the art: Using natriuretic peptide levels in clinical practice (2008, background): “They showed that this approach reduced the composite primary endpoint of HF deaths and HF hospitalisation [85] compared to guidelinedirected therapy.”
• Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine (2010, background): “It is possible that the best way to keep off excess fluid to avoid decompensation is to improve overall cardiac function using evidence-based therapies such as beta-blockers, angiotensin-converting enzyme inhibitors, aldosterone receptor antagonists, and cardiac resynchronization therapy, although d”
• ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 ‡ (2008, unknown): “Natriuretic peptides may also be useful in assessing prognosis prior to hospital discharge and in monitoring the effectiveness of HF therapy.(61,62) .”
• 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. (2017, background): “cardiovascular outcomes (43-62), there are insuffic ient data to inform specific guideline recommendati ons”